Precision Oncology
Oncotype DX Colon Recurrence Score®
Colon cancer is the third most prevalent cancer for both men and women in the United States. It’s also the second most common cause of cancer-related deaths — yet no two colon cancer patients, or their treatment needs, are the same.
Each patient has an individualized level of risk, making the choice of treatment different for everyone. Part of the treatment decision making process involves understanding the likelihood of the colon cancer returning and how a patient’s condition is managed after surgery.
The Oncotype DX Colon Recurrence Score test is clinically validated to quantify the risk of recurrence of patients with anatomic stage II, MMR-P and stage III A/B colon cancers.
The 12-gene genomic test (seven cancer-related genes and five reference genes) looks at the underlying biology of a patient’s tumor so patients can choose a treatment that fits their unique situation.
Looking for clarity about the next step?
Our team can help you understand test access and guide you through the process with confidence.
.jpg)
